alexa Anti-microRNA-378a Enhances Wound Healing Process By Up-regulating Integrin Beta-3 And Vimentin
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th World Congress on Cancer Science & Therapy
October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Burton B Yang, Haoran Li, William W Du, Leslie Chang, Shaan Gupta and Anna Khorshidi
ScientificTracks Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.033
One criterion for microRNA identification is based on their conservation across species, and prediction of miRNA targets by empirical approaches using computational analysis relies on the presence of conservative mRNA 3?UTR. Because most miRNA target sites identified are highly conserved across different species, it is not clear whether miRNA targeting is speciesspecific. We aligned all 3?UTRs of fibronectin and observed significant conservation of all 20 species. Twelve miRNAs were predicted to target most fibronectin 3?UTRs, but rodent fibronectin showed potential binding sites for five different miRNAs. One of them, the miR-378, contained a complete matching seed-region for all rodent fibronectin, which could not be found in any other species. We have previously demonstrated that expression of miR-378 promoted tumorigenesis and angiogenesis by targeting human Fus-1 and Sufu. Consistent with this result, we found that ectopic expression of miR-378 inhibited cell differentiation and promoted cell invasion. To understand the specific targeting of miR-378 on fibronectin, we expressed miR- 378 in mouse breast cancer cells and found that overexpression of miR-378 enhanced cancer cell proliferation, migration, invasion, and colony formation, resulting in inhibition of tumor growth. Induced expression of fibronectin produced opposite results, while silencing fibronectin displayed similar effects as miR-378. To understand how miR-378 works, we generated transgenic mice expression miR-Pirate378 can not only arrest the functions of mature miRNAs by binding to them but it can also induce the ?mis-processing? of the target miRNA producing a non-functional truncated miRNA. This approach involves generating an expression construct that produces a RNA fragment with sixteen repeat sequences. The construct is named miR-Pirate or microRNA-interacting RNA producing imperfect RNA and tangling endogenous miRNA. The transcript of the construct contained mismatches to the seed region, and thus it would not target the potential targets of the miRNA under study. The homology of the construct is sufficiently high allowing the transcript to block miRNA functions. The functions of the construct were validated in cell cultures, in tumor formation assays, and in transgenic mice stably expressing this construct. We showed that miR-Pirate378 transgenic mice display enhanced wound healing. Expression of vimentin and b3 integrin, two important modulators of wound healing, is elevated remarkably in the transgenic mice. To explore the possibility of adopting this approach in gene therapy, we transfected cells with synthetic miR-Pirate and obtained the results we expected. The miR-Pirate, expressed by the construct or synthesized chemically, was found to be able to specifically pirate and silence a mature miRNA through its dual roles and thus could be clinically applied for miRNA intervention. Migration assays showed a greater mobility in the miR-Pirate378-transfected cells, which was due to up-regulation of vimentin and b3 integrin. Both molecules were confirmed as targets of miR-378, and thus their expression could be rescued by miR-Pirate378. Overexpression of vimentin also contributed to fibroblast differentiation, and up-regulation of b3integrin was responsible for increased angiogenesis. Treatment with miR-Pirate378 conjugated to nanoparticle enhanced wound healing in mice. Thus, we have demonstrated that knockdown of miR-378 could increase the expression of its target proteins, vimentin and b3 integrin, which accelerated fibroblast migration and differentiation in vitro and enhanced wound healing in vivo.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

1-702-714-7001Extn: 9042

General Science

Andrea Jason

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001Extn: 9042

© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version